Last Updated on July 23, 2024 by The Health Master
Drug alert
Drug alert: Download the list of NSQ samples for June 2024, the link is given below: 61 drug samples declared as not of standard quality (NSQ), nationwide.
NSQ Lists are given below the article
Out of these 61 samples, 31 were declared NSQ by CDSCO and 30 were declared NSQ by various STATES across India.
Out of these 13 samples were declared NSQ by various STATES across India, 5 were declared as Misbranded.
Details of the NSQ samples declared by STATES is as under:
| Sr. | Name of STATES | Number of NSQ samples declared |
| 1 | Kerala | 7 |
| 2 | Maharashtra | 23 |
| Total | 30 |
NOTE:
- NSQ data was not received as per Format & in EXCEL SHEET from State Drugs Licensing Authorities of Rajasthan (PDF format) and Orissa (PDF Format). for the Month of June, 2024 as per DCG(I) Circular dated 09.02.2024.
- State Drugs Licensing Authorities of Andhra Pradesh, Arunachal Pradesh, Assam, Bihar, Chhattisgarh,Goa,Gujarat, Haryana, Himachal Pradesh, Manipur, Meghalaya, Mizoram, Nagaland, Odisha, Punjab, Sikkim, Tamil Nadu, Pondicherry,Telangana,Delhi,Uttarakhand, West Bengal, Andaman & Nicobar, Dadar and Nagar Haveli; Daman and Diu, Lakshadweep have not submitted any data in respect of the Not of Standard Quality (NSQ) Alert for the Month of June, 2024 as per DCG(I) Circular dated 09.02.2024.
Drug alert: Previous months
May 2024: Out of these 52 samples, 39 were declared NSQ by CDSCO and 13 were declared NSQ by various STATES across India.
April 2024: Out of these 50 samples, 33 were declared NSQ by CDSCO and 17 were declared NSQ by various STATES across India.
During the month of March 2024, the authorities tested 931 samples, out of which 864 were of standard quality. The number of samples declared as not of standard quality was 66, with one being misbranded and none being spurious.
During the month of February 2024, the authorities tested 1167 samples, out of which 1018 were of standard quality. The number of samples declared as not of standard quality was 58, with none being misbranded and two being spurious.
During the month of January 2024, the authorities tested 932 samples, out of which 886 were of standard quality. The number of samples declared as not of standard quality was 46, with none being misbranded and none being spurious.
During the month of December 2023, the authorities tested 1008 samples, out of which 930 were of standard quality. The number of samples declared as not of standard quality was 78, with none being misbranded and none being spurious.
During the month of November 2023, the authorities tested 1197 samples, out of which 1133 were of standard quality. The number of samples declared as not of standard quality was 62, with one being misbranded and one being spurious.
During the month of October 2023, the authorities tested 1105 samples, out of which 1044 were of standard quality. The number of samples declared as not of standard quality was 61, with none being misbranded and none being spurious.
During the month of September 2023, the authorities tested 1188 samples, out of which 1126 were of standard quality. The number of samples declared as not of standard quality was 62, with none being misbranded and none being spurious.
During the month of August 2023, the authorities tested 1166 samples, out of which 1118 were of standard quality. The number of samples declared as not of standard quality was 48, with none being misbranded and none being spurious.
During the month of July 2023, the authorities tested 1306 samples, out of which 1252 were of standard quality. The number of samples declared as not of standard quality was 51, with none being misbranded and 3 being spurious.
During the month of June 2023, the authorities tested 1273 samples, out of which 1225 were of standard quality. The number of samples declared as not of standard quality was 48, with none being misbranded and one being spurious.
The test samples were drawn by the zonal and sub-zonal offices of CDSCO, and tested in the drug testing laboratories, i.e CDLs, CDTLs, and RDTLs, in Kolkata, Mumbai, Hyderabad, Chandigarh, Indore, and Guwahati.
Drug alert: 52 drug samples declared as NSQ in May 2024
Drug alert: 50 drug samples declared as NSQ in April 2024
Drug alert: 66 out of 931 samples declared as NSQ in March 2024
Drug alert: 58 out of 1167 samples declared as NSQ in February 2024
Drug alert: 46 out of 932 samples declared as NSQ in January 2024
Procedure to obtain License to Manufacture drugs for testing and analysis purposes
Procedure to obtain license for Commercial Testing Laboratories
Latest Notifications: Testing Laboratories
Commercial Testing Laboratories
Commercial Testing Laboratories: Procedure
Updated list of Medical Device Testing Laboratories (MDTLs)
List of Laboratory Instruments for Pharma & Cosmetics Industry
Calibration of Laboratory Instruments
NABL: List of NABL Accredited Testing Laboratories
NABL 164 released : Guidelines for Inter-laboratory comparison
NABL releases NABL 136: specific criteria for X-Ray equipment
NABL 126: Specific criteria for calibration of Medical Devices
Laboratory Waste Management, Types and Its Disposal
NABL certification procedure for Laboratories
Quality Assurance Vs Quality Control in the Pharma Industry
NABL certification for Laboratories: Let’s understand
Major FDA audit findings about Equipment and Instruments
Equipment and Instruments: Maintenance, difference and importance in the Pharma Industry
Upcoming events: Pharma, Cosmetics, Homoeopathy & Medical Devices
Cosmetics Testing in India: A Comprehensive Guide
Difference between Validation and Calibration in the Pharma Industry
Calibration of Laboratory Instruments
Difference: Disintegration and Dissolution test in pharma industry
Understanding DQ, IQ, PQ, and OQ in the Pharma Industry
Duties and responsibilities of QA person in Pharma Industry
Dissolution test: Importance in Pharma Industry
Licensing procedure for manufacturing of Drugs
Procedure to obtain license for manufacturing of Cosmetics
Procedure to obtain license for manufacturing of Homoeopathic Medicines
Procedure to obtain license for manufacturing of Medical Devices
Procedure to obtain License to Manufacture drugs for testing and analysis purposes
Procedure to obtain license for Blood Centre (Blood Bank)
Procedure to obtain license for Commercial Testing Laboratories
Requirements for License for Repacking of Drugs: Key points
Medical Device recall: USFDA classifies recall of this implant as ‘Most Serious’
Gujarat FDCA Revokes Licenses of 7 Drug Testing Laboratories
DCGI: Withdraw Cancer drug ‘Olaparib’ for these treatments
USFDA approval granted for Asthma Treatment Drug
USFDA inspection concluded at Solara Pharma without any observations
NPPA revised Ceiling price of 1 scheduled formulation: May 2024
FSSAI: Food Labelling and Display – Chapter-6
Indian Regulators Crack Down on Unapproved Antibiotics to Fight Misuse
List of Drugs declared as NSQ by CDSCO for the Month of June– 2024.
| A. CDSCO/Central Laboratories | |||||||
| S.No | Product/Drug Name | Batch No. | Manufacturing Date | Expiry Date | Manufactured By | NSQ Result | Reported by CDSCO Laboratory |
| 1. | Propylene Glycol I.P. | PG- IP/2023- 24/2355 | 11/2023 | 10/2028 | M/s. Manali Petrochemicals Ltd., Manali, Chennai- 600068, India | Relative Density | CDL, Kolkata |
| 2. | Propylene Glycol USP/IP | BT1205B0 4072023 | 07/2023 | 07/2024 | M/s. Balaji Amines Limited, Plot No. F- 104, Chinchoili M.I.D.C., Tq. Mohol, Distt. Solapur – 413 255, Maharastra | Relative Density | CDL, Kolkata |
| 3. | Compound Sodium Lactate Injection I.P., 500 ml (Ringer Lactate Solution for Injection) | P2401050 08 | 01/2024 | 12/2025 | M/s. Vision Parenteral Pvt. Ltd., A-2-44, 45, Sector-15, GIDA Industrial Area, Gorakhpur -273209 (U.P.), India | Bacterial endotoxins | CDL, Kolkata |
| 4. | Esomeprazole Gastro- Resistant Tablets IP 40 mg (Esomedge- 40) | GD23083 | 07/2023 | 06/2025 | M/s. GlenSmith Labs Private Limited, Mfg. by: Skymap Pharmaceuticals Pvt. Ltd., B-3, Dev Bhoomi Industrial Estate, Puhana Iqbalpur Road, Roorkee 247 667. | Dissolution | CDL, Kolkata |
| 5. | Gentamicin Sulphate Injection I.P. 2 ml | 323-216 | 03/2023 | 02/2025 | M/s. Zee Laboratories Ltd., Behind 47, Indl. Area, Paonta Sahib – 173025 | Description & Particulate matter | CDL, Kolkata |
| 6. | Frusemide Injection IP 2 ml (FRUSEMIDE) | FRA12347 | 12/2023 | 11/2025 | M/s. Nandani Medical Laboratories Pvt. Ltd., 221/5, Bicholi Hapsi, Kanadia Road, Indore | pH | CDL, Kolkata |
| 7. | Ceftriaxone for Injection I.P. 1 gm | DC30119 | 10/2023 | 09/2025 | M/s. Captab Biotec Unit-II, Plot No-125, E.P.I.P Road, Mauja Jharmajri, Baddi, Distt.-Solan H.P. | Particulate matter | CDL, Kolkata |
| 8. | Amoxycillin & Potassium Clavulanate Injection IP 1.2 gm | 23AP04 | 05/2023 | 04/2025 | M/s. Sai Parenterals Limited, D1 & D4, Survey No. 280, Phase- V, IDA, Jeedimetla, Hyderabad-500 055, TS. | Clarity of Solution and Assay of Potassium Clavulanate | CDL, Kolkata |
| 9. | Cefixime & Ofloxacin Tablets (CEFIKAM OF 200) | DB230057 | 02/2023 | 01/2025 | M/s. Daxin Pharmaceuticals Pvt. Ltd., Plot No-121-122, EPIP, Jharmajri Phase-1, Teh. Baddi, Distt. Solan (H.P.) 174 103. | Assay of Cefixime Trihydrate & Assay Ofloxacin | CDL, Kolkata |
| 10. | Propylene Glycol USP | 97220141 13 | 11/2023 | 10/2028 | M/s. Shell Eastern Chemicals, The Metropolis Tower, 1, 9 North Buona, Visla Drive 07 01 Singapore 138588 | Specific Gravity | CDL, Kolkata |
| 11. | Ranitidine Hydrochloride Tablets (Ranylaj-150) | GTDE3019 | 05/2023 | 04/2025 | M/s. Francis Remdies (India) Pvt.Ltd., Vill- Mandawali, Roorkee, Distt. Haridwar (U.K.) 247670 | Description | CDL, Kolkata |
| 12. | Glipizide and Metformin Tablets IP (Glynase-MF) | 04010026 | 11/2023 | 04/2025 | M/s. USV Private Limited, At: B-249/B- 250, II Stage, Peenya Industrial Estate, Bangalore-560058 | Dissolution of Glipizide | CDL, Kolkata |
| 13. | Exo Cheri (Dextromethorp han Hydrobromide Chlorpheniramin e Maleate Pheylephrine Hydrochloride Cough Syrup) | L/040618 | 04/2024 | 01/2026 | Exotic Pharma, 91/1, G.I.D.C., GODHRA Dist.- Panchmahal, Gujarat- 389001 | pH | CDTL-Mumbai |
| 14. | Etamsylat Tablets 500 mg | ELT1104 | 02/2024 | 07/2024 | Unicure India Ltd., C- 21, 22 & 23, Sector-3, Noida-201 301, Distt. Gautam Budh Nagar (U.P) | Description | CDTL-Mumbai |
| 15. | Tranexamic Acid Tablets I.P. 500 mg | GT31022 | 01/2024 | 12/2025 | OMEGA PHARMA KhasraNo.-482, Village-Saliyar, Roorkee-247667, Distt.-Haridwar (Uttarakhand) | Related substances | CDTL-Mumbai |
| 16. | Extuss-D (Dextromethorp han HBR, Chlorpheniramin e Maleate & Phenylephrine HCL Syrup) | 2402168 | 02/2024 | 01/2026 | Brij Healthcare Pvt. Ltd., 51/10, G.I.D.C Estate, Motipura, Himatnagar, Gujarat 383001 | Assay of Phenylephrin e Hydrochloride | CDTL-Mumbai |
| 17. | IRON & FOLIC ACID SYRUP IP | RIFS-209 | 04/2024 | 09/2026 | M/s. Revat Laboratories Pvt. Ltd., Works at : 12-321, Opp. I.D.A, Kurnool Road, Pernamitta, Ongole-523002 | pH and Assay of Folic Acid | CDTL, Hyderabad |
| 18. | Prednisolone Tablets IP 10 mg | PRDT- 1007 | 11/2024 | 10/2024 | WINGS BIOTECH LLP, 43 & 44, HPSIDC, Industrial Area, Baddi-173205 (H.P.) | Assay of Prednisolone | RDTL Chandigarh |
| 19. | Aloevera, Glycerin and Vitamin-E Soap (D-Soft Soap) | COS-130 | 03/2024 | 02/2026 | Samanyu Skin Care, Plot No. 191, HPSIDC, Baddi, Distt. Solan (H.P.)-1732025 | Matter insoluble in alochol | RDTL Chandigarh |
| 20. | Aloevera, Glycerin, Vitamin-E and Jojoba oil (Synmoist Soap) | COS-132 | 03/2024 | 02/2026 | Samanyu Skin Care, Plot No. 191, HPSIDC, Baddi, Distt. Solan (H.P.)-1732025 | Matter insoluble in alochol | RDTL Chandigarh |
| 21. | Aloevera+Glyce rin+Almond Oil and Vitamin-E Soap (Aqualux Soap) | COS-131 | 03/2024 | 02/2026 | Samanyu Skin Care, Plot No. 191, HPSIDC, Baddi, Distt. Solan (H.P.)-1732025 | Matter insoluble in alochol | RDTL Chandigarh |
| 22. | Fexofenadine Hydrochloride Tablets IP (MANOFEX-180 TABLETS) | CT232407 15A | 08/2023 | 07/2025 | CMG BIOTECH PVT. LTD., (Unit-II) Plot No. 58, Phase III, Industrial Area, Sansarpur Terrac HP-176501 | Dissolution (In 10 minutes) and (in 30 minutes) | RDTL Chandigarh |
| 23. | Norfloxacin Oral Suspension (Ridnor Suspension) | RL230022 | 03/2023 | 02/2025 | RIDLEY LIFE SCIENCE PVT. LTD., Unit II : D-1566 DSIDC, Ind. Complex, Narela, Delhi-110040 | Description and Total Fungal Count | RDTL Chandigarh |
| 24. | Albendazole Tablets IP | MS1AO22 01 | 07/2022 | 06/2025 | MAXTAR BIO- GENICS, Khasra No. 705, Vill. Malku Majra, Nalagarh Road, Baddi, Distt.Solan-173205 (H.P.)-India | Dissolution | RDTL Chandigarh |
| 25. | Pantoprazole Gastro- Resistant Tablets IP 40 mg. | PGR-07 | 01/2024 | 12/2025 | Agron Remedies Pvt. Ltd., Sarverkhera, Moradabad Road, Kashipur-244713 (Uttarakhand) | Dissolution | RDTL, Guwahati |
| 26. | Co-trimoxazole Tablets IP (S- tron Tablets SS) | ST-223 | 06/2023 | 05/2025 | High Tech Pharma, 49, Khandelwal compound, Palda, Indore (MP) | Dissolution (Trimethopri m and Sulphametho xazole) | RDTL, Guwahati |
| 27. | Montelukast Sodium and Levocetirizine Hydrochloride Tablets IP (Levmont) | ST23- 384D | 05/2023 | 04/2025 | M/s Symbiosis Pharmaceuticals Pvt. Ltd.,, Suketi Road, Kala Amb Distt. Sirmour, Himachal Pradesh – 173030 | Dissolution of Montelukast Levocetirizine hydrochloride | RDTL, Guwahati |
| 28. | Levocetirizine Dihydrochloride and Montelukast Sodium Tablets IP | 23112701 | 03/2023 | 02/2025 | MERCURY LABORATORIES LIMITED., Unit No.2, Halol Baroda Road, Village: Jarod. Tal: Waghodia, Dist: Vadodara- 391510 | Dissolution of Montelukast | RDTL, Guwahati |
| 29. | Iron and Folic Acid Syrup IP | IFIS23015 | 08/2023 | 01/2025 | Galpha Laboratories Limited, Village- Thana, Baddi, Himachal Pradesh- 173205 | Assay of Folic Acid | RDTL, Guwahati |
| 30. | Etoricoxib Tablets I.P. 90 mg. | ECX-2304 | 08/2023 | 07/2025 | Apple Formulations Private Limited, Plot No. 208, Kishanpur, Roorkee – 247667 (U.K.) | Dissolution | RDTL, Guwahati |
| 31. | Mannitol Injection I.P. (20% w/v) | M1M30038 | 07/2023 | 06/2025 | Kunal Remedies Pvt. Ltd., Khasra 284, Vill. Anaura Kala Faizabad Road, Lucknow 226028, (UP), India | Test for Sterility | RDTL, Guwahati |
List of Drugs declared as NSQ by STATES for the Month of June– 2024.
| B. State Laboratories | |||||||
| S.No | Product/Drug Name | Batch No. | Manufacturing Date | Expiry Date | Manufactured By | NSQ Result | Reported by CDSCO Laboratory |
| 1. | Liquid Paraffin IP | EP4032 | 01/24 | 12/26 | Repacked by :- Kerala State Drugs & Pharmaceuticals Ltd, Kalavoor.P.O, Alappuzha | It fails the test light absorption as per IP | Drugs Testing Laboratory Thiruvananthapura m |
| 2. | Losartan Potassium Tablets IP 50 mg | HLOA06 | 11/23 | 10/25 | Hindustan Antibiotics Ltd, at II, W.E.A, Faridabad- 121 001(Haryana) R.O, Pimpri, Pune -411 018 | It fails the test ‘Dissolution’ as per IP | Drugs Testing Laboratory Thiruvananthapura m |
| 3. | Amloheart-AT [Amlodipine Besylate and Atenolol Tablets] | LE223030 | 03/23 | 02/25 | Lividus Pharmaceuticals pvt.Ltd, ikeva, Level2, Agnito Tech park,141 Kandachavadi, Near, Perungudi, OMR, Chennai-600096 | It fails the test ‘Assay’ of Amlodipine Besylate | Drugs Testing Laboratory Thiruvananthapura m |
| 4. | Bacotil-200 [Cefpodoxime Proxetil Tablets USP ] | ZTB-148 | 03/24 | 02/26 | Zenith Healthcare Ltd works: 388/34, Changodarlnd. Estate, Sarkhej Bavla Highway, Changodar- 382213 (Gujarat) | It fails the test ‘Dissolution’ as per USP | Drugs Testing Laboratory Thiruvananthapura m |
| 5. | Oseltamivir Cap IP 75 mg | D 0444/24- 25 | Supplied by Kerala Medical Services Corporation Ltd, Thycaud P.O, Thiruvananthapuram-14 | The sample does not conform to IP standard with respect to the ‘Descriptive part’ of hard gelatin capsules | Drugs Testing Laboratory Thiruvananthapura m | ||
| 6. | Haridrakhandam | 207/23 | 03/24 | 02/26 | Bhaskaravilasam Vaidyasala, Panayamuttom, Nedumangadu Thiruvananthapuram 695 561 | It fails the test ‘pH’ as per API | Drugs Testing Laboratory Thiruvananthapura m |
| 7. | Yogarajaguggulu | 209/21 | 03/22 | 3 yrs from the date of mfg | Bhaskaravilasam Vaidyasala, Panayamuttom, Nedumangadu, Thiruvananthapuram 695 561 | It fails the test ‘Alcohol soluble Extractive and pH’ as per API | Drugs Testing Laboratory Thiruvananthapura m |
| 8. | CANDITRAL 100 (ITRACONAZOLE CAPSULE B.P. 100 MG) | 5230123 | Jan-23 | Jun-25 | GLENMARK PHARMACEUTICALS LTD. | THE SAMPLE DOES NOT COMPLY WITH B P REQUIREMENTS FOR DISSOLUTION TEST | Maharashtra |
| 9. | Lytraco 200 Itraconazole Capsules 200 mg | SLP-22445 | Feb-23 | Jan-25 | STERLIFE PHARMA PVT. LTD. | THE SAMPLE DOES NOT COMPLY WITH B P REQUIREMENTS FOR DISSOLUTION TEST THE SAMPLE IS OFFICIAL IN B P 2021 THEREFORE THE SAMPLE IS MISBRANDED VIDE SECTION 17(b) AND RULE 96 OF THE DRUGS AND COSMETICS ACT 1940 AND RULES 1945. | Maharashtra |
| 10. | MONTOR -LC TABLET (MONTELUKAST SODIUM & LEVOCETRIZINE DIHYDROCHLORI DE TABLET I.P.) | B18523001 | Jan-23 | Dec-24 | TORQUE PHARMACEUTICALS PVT. LTD. | THE SAMPLE DOES NOT COMPLY WITH I P REQUIREMENTS FOR DISSOLUTION TEST | Maharashtra |
| 11. | MONTICET-L Tablets ( Montelukast & Levocetirizine Hydrochloride Tablets) | TP-7581 | Sep-22 | Aug-24 | TICOMA PHARMACIA | THE SAMPLE DOES NOT COMPLY WITH IP REQUIREMENTS FOR DISSOLUTION TEST FOR MONTELUKAST. THE SAMPLE IS OFFICIAL IN 1 P 2018 THEREFORE THE SAMPLE IS MISBRANDED VIDE SECTION 17(b) AND RULE 96 OF THE DRUGS AND COSMETICS ACT 1940 AND RULES 1945. | Maharashtra |
| 12. | Levocetrizine Dihydrochloride & Montelukast Sodium Tablets I.P. Zeemont | T22H370C | Aug-22 | Jul-24 | Bajaj Formulations | THE SAMPLE DOES NOT COMPLY WITH IP REQUIREMENTS FOR DISSOLUTION TEST FOR MONTELUKAST. | Maharashtra |
| 13. | VolKast Kid Syrup 60 ml. | ABS- 2301022 | Jan-23 | Dec-24 | Amentis Biotech Pvt. Ltd. | CONTENT OF MONTELUKAST AND LEVOCETIRIZINE GYDROCHLORIDE IN THE SAMPLE IS LESS (i.e. MONTELUKAST IS 10.50% AND LEVOCETIRIZINE HYDROCHLORIDE IS 71.88% OF THE STATED AMOUNT) THAN THE PERMISSIBLE LIMITS. | Maharashtra |
| 14. | Levetiracetam Tablets U.S.P.500 Mg (LEVEEG-500) | T23D050A | Apr-23 | Mar-25 | BAJAJ FORMULATIONS | THE SAMPLE DOES NOT COMPLY WITH USP REQUIREMENTS FOR DISSOLUTION. | Maharashtra |
| 15. | M2 Pan-DSR (Pantoprazole Gastro-resistant & Domperidone Prolonged-release Capsules IP) | CWHC-283 | Oct-22 | Sep-24 | COSWAY PHARMACEUTICALS | THE SAMPLE DOES NOT COMPLY WITH IP REQUIREMENTS FOR DISSOLUTION OF PANTOPRAZOLE AT ACID STAGE | Maharashtra |
| 16. | Omeford – 40 | SNT-220421 | Sep-22 | Aug-24 | SVR HEALTHCARE (A GMP Certified Company) | THE CONTENT OF OMEPRAZOLE IN THE SAMPLE IS LESS (l.e. 40.84% OF LABELLED AMOUNT) THAN THE SCHEDULE V LIMITS | Maharashtra |
| 17. | COZOL- D(Omeprazole with Domperidone Capsules) | AC1952 | Jul-23 | Jun-25 | ALICON PHARMACEUTICAL PVT LTD | THE SAMPLE DOES NOT COMPLY WITH IP REQUIREMENTS FOR OMEPRAZOLE AND DOMPERIDONE CAPSULES FOR THE DISSOLUTION TEST (OMEPRAZOLE). THE SAMPLE IS OFFICIAL IN IP. | Maharashtra |
| 18. | DRPLAN-DSR (Pantoprazole Gasto-resistant & Domperidone Prolonged-release Capsules IP) | AC2209003A | Sep-22 | Aug-24 | ADDII BIOTECH PVT. LTD. | THE SAMPLE DOES NOT COMPLY WITH IP REQUIREMENTS FOR PANTOPRAZOLE AND DOMPERIDONE CAPSULES FOR THE DISSOLUTION TEST (PANTOPRAZOLE) . | Maharashtra |
| 19. | SOFTOM-D Omeprazole and Domperidone Capsules IP | UD2C- 23252B | Apr-23 | Mar-25 | ULTRA DRUGS PVT. LTD. (UNIT-II) | THE SAMPLE DOES NOT COMPLY WITH IP REQUIREMENTS FOR OMEPRAZOLE AND DOMPERIDONE CAPSULES FOR THE DISSOLUTION TEST (OMEPRAZOLE). | Maharashtra |
| 20. | OMEPRAZOLE & DOMPERIDONE CAPSULES (REMIZOLE-D) | SPC230578 C | Mar-23 | Feb-25 | SALUS PHARMACEUTICALS | THE SAMPLE DOES NOT COMPLY WITH IP REQUIREMENTS FOR OMEPRAZOLE AND DOMPERIDONE CAPSULES FOR THE DISSOLUTION TEST (OMEPRAZOLE). | Maharashtra |
| 21. | PANTOPRAZOLE (EC) & DOMPERIDONE (SR) CAPSULES IP (PANTIAC-DSR) | PTRC-149 | Feb-23 | Jan-25 | IOSIS REMEDIES PVT. LTD. | THE SAMPLE DOES NOT COMPLY WITH IP REQUIREMENTS FOR PANTOPRAZOLE AND DOMPERIDONE CAPSULES FOR THE DISSOLUTION TEST (PANTOPRAZOLE) | Maharashtra |
| 22. | DYNACID SUSPENSION (aluminium, magnesium & simethicone oral suspension IP.) | BULH23008 | Apr-23 | Mar-25 | Leeford Healthcare Ltd. | 1) THE SAMPLE DOES NOT COMPLY WITH I.P. REQUIREMENTS FOR TOTAL AEROBIC VIABLE | Maharashtra |
| COUNT IN TEST FOR MICROBIAL CONTAMINATION. 2) TOTAL AEROBIC VIABLE COUNT OF THE SAMPLE IS 20993128 CFU/GM. (1.P. LIMIT-TOTAL AEROBIC VIABLE COUNT OF THE SAMPLE – NOT MORE THAN 100 CFU/GM | |||||||
| 23. | ELTHROM-200 (Azithromycin oral suspension IP) 15ML | G-042/5045 | May-23 | Apr-25 | ELFIN DRUGS PVT. LTD. | CONTENT OF AZITHROMYCIN IN THE SAMPLE IS LESS (72.96% OF LABELLED AMOUNT) THAN THE IP LIMIT WITH RESPECT TO ABOVE PROTOCOL. (IP LIMIT-90.0%- 110.0%) | Maharashtra |
| 24. | Alpracan 0.5 Tablets (Alprazolam Tablets) | T2455 | Oct-22 | Sep-25 | Evolet Pharmaceutical Pvt. Ltd. | THE SAMPLE DOES NOT COMPLY WITH IP REQUIREMENTS FOR ALPRAZOLAM TABLETS FOR THE DISSOLUTION TEST WITH RESPECT TO ABOVE PROTOCOL. | Maharashtra |
| 25. | RABEPP TABLETS (Rabeprazole Sodium Tablets IP) | ATG2K135 | Nov-22 | Oct-24 | ANROSE PHARMA | CONTENT OF RABEPRAZOLE SODIUM IM THE SAMPLE IS LESS (65.04% OF THE LABELLED AMOUNT) THAN THE IP LIMIT WITH RESPECT TO ABOVE PROTOCOL. (IP LIMIT 90.0% – 110.0%) | Maharashtra |
| 26. | INFI-650 TABLETS (PARACETAMOL TABLETS I.P. 650 mg) | AT-100008 | Dec-22 | Nov-25 | ABARIS HEALTHCARE | THE SAMPLE DOES NOT COMPLY WITH IP REQUIREMENTS FOR DISSOLUTION TEST. | Maharashtra |
| 27. | CUCID-DM | CDMC501 | May-23 | Apr-25 | TULBROS FORMULATIONS | THE SAMPLE DOES NOT COMPLY WITH IP REQUIREMENTS FOR DISSOLUTION TEST FOR OMEPRAZOLE IN ACID STAGE. | Maharashtra |
| 28. | Virpan-40 | T-2306031A | Jun-23 | May-25 | WHITE ENGLE LABORATORIES | THE SAMPLE DOES NOT COMPLY WITH IP REQUIREMENTS FOR DISSOLUTION IN BUFFER STAGE. | Maharashtra |
| 29. | Pantakos-40 (Pantoprazole Gastro-resistant Tablets IP ) | CCT231092 B | Sep-23 | Aug-25 | Cent Cure Pvt Ltd. | THE SAMPLE DOES NOT COMPLY WITH IP REQUIREMENTS FOR DISSOLUTION IN BUFFER STAGE. | Maharashtra |
| 30. | Rosumep ASP 10/75mg Capsules | PBWGM04 | Sep-23 | Aug-25 | Pure & Care Healthcare Pvt. Ltd. | THE SAMPLE DOES NOT COMPLY WITH IP FOR THE TEST “RELATED SUBSTANCES – ROSUVASTATIN”. | Maharashtra |
NOTE:
- NSQ data was not received as per Format & in EXCEL SHEET from State Drugs Licensing Authorities of Rajasthan (PDF format) and Orissa (PDF Format). for the Month of June, 2024 as per DCG(I) Circular dated 09.02.2024.
- State Drugs Licensing Authorities of Andhra Pradesh, Arunachal Pradesh, Assam, Bihar, Chhattisgarh,Goa,Gujarat, Haryana, Himachal Pradesh, Manipur, Meghalaya, Mizoram, Nagaland, Odisha, Punjab, Sikkim, Tamil Nadu, Pondicherry,Telangana,Delhi,Uttarakhand, West Bengal, Andaman & Nicobar, Dadar and Nagar Haveli; Daman and Diu, Lakshadweep have not submitted any data in respect of the Not of Standard Quality (NSQ) Alert for the Month of June, 2024 as per DCG(I) Circular dated 09.02.2024.
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
